Alkermes settles Lybalvi patent suit with Teva, licenses generic entry for 2039Nov 12PartnershipAlkermes, Inc.Minerva NeurosciencesUpdated
Minerva reports Q2 2026 results, confirms C19 trial timeline for roluperidoneAug 7Quarterly updateMinerva Neurosciencesroluperidone